Publications by authors named "Buononato D"
Psoriasis and obesity, while distinct, are inter-related inflammatory conditions. Adipose tissue (AT)-derived mediators could be pathogenically active in triggering and/or amplifying psoriatic skin inflammation and, vice versa, skin inflammation could drive increased adiposity that triggers the development of several chronic conditions. Gaining insight into their intricate relationship could be essential for effective management and treatment.
View Article and Find Full Text PDFHappiness across the borders-A cross-sectional study among patients with psoriasis and atopic dermatitis in Europe.
J Eur Acad Dermatol Venereol
August 2024
Background: Dermatological research has traditionally concentrated on evaluating mental comorbidities, neglecting positive concepts like happiness. Initial studies indicate that psoriasis and atopic dermatitis (AD) impair the happiness of those affected. Considering global happiness variations, this study aimed to explore the disease- and country-specific differences in disease-related quality of life and happiness, and potential influential factors on heuristic happiness among psoriasis and AD patients in Europe.
View Article and Find Full Text PDFArticle Synopsis
- Genital psoriasis affects about 60% of psoriasis patients, presenting challenges in treatment, but IL-17 inhibitors like bimekizumab have shown promise for this difficult condition.
- A 16-week study on 65 participants revealed that 98.4% achieved clear improvement in genital psoriasis, demonstrating both effective symptom relief and enhanced quality of life.
- The results indicate bimekizumab could be a beneficial treatment for genital psoriasis, but further research with larger and longer studies is needed to confirm these findings.
Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, the burden on society is substantial. Managing this condition presents challenges such as long-term treatment, poor patient compliance, therapy side effects, and economic feasibility.
View Article and Find Full Text PDFIntroduction: Tildrakizumab is a humanized IgG1κ monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, approved in 2018 for the treatment of patients with moderate-to-severe chronic plaque psoriasis.
Objectives: This study aimed to evaluate the effectiveness, safety and survival of tildrakizumab in the medium term (48 weeks) in psoriatic patients failure to previous biologic treatment in a real world setting.
Methods: This was a retrospective, multicenter observational study that included adult patients with moderate-to-severe plaque psoriasis, failure to previous biologic therapy, consecutively treated with tildrakizumab.
Background: Managing a pregnant patient with chronic spontaneous urticaria (CSU) is often challenging. Recent data have shown that most CSU treatments in pregnant patients are second-generation H1 antihistamines (sgAHs), while data on the safety of omalizumab are scant.
Objectives: To evaluate, in a routine clinical practice setting, the efficacy and safety of omalizumab in patients with severe CSU refractory to sgAHs who either became pregnant during treatment or who started the drug during pregnancy.
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting Interleukin-17 A and F, is effective for moderate-to-severe plaque psoriasis, though real-world data is limited.
- A retrospective study in 19 Italian hospitals assessed 237 patients treated with bimekizumab, measuring psoriasis severity at 4 and 16 weeks based on PASI scores.
- Results showed significant improvements in skin clearance and quality of life, with 75.4% achieving clear skin by week 16, and side effects were minimal and manageable.
Article Synopsis
- Down syndrome (DS) is the most prevalent chromosomal disorder, with patients often experiencing skin issues like psoriasis and atopic dermatitis, which can be treated with biological drugs.
- A study examined the effectiveness of these drugs in 7 patients (4 adults and 3 minors), revealing significant improvement in psoriasis symptoms over 24 weeks, with reductions in severity and impact on quality of life.
- The findings suggest that while no official treatment guidelines for psoriasis in DS patients exist, anti-TNFα drugs like adalimumab and newer anti-interleukin medications show promise with good tolerability and effectiveness.
Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related aspects such as physical, psychological and mental functioning. Here, we conducted a review of studies relating to candidate biomarkers and indicators associated with QoL impairment in PSO and AD.
View Article and Find Full Text PDFFecal calprotectin has emerged as a significant, validated, and non-invasive biomarker allowing for the evaluation of inflammatory bowel disease. Our study assessed the reliability of the use of faecal calprotectin as a valuable tool in the management of psoriatic patients on biological therapy. This was a single-centre prospective study including adult patients affected by moderate-to-severe psoriasis starting biological therapy.
View Article and Find Full Text PDF